EXPRS2 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - ExpreS2ion Biotech Holding AB

Watchlist Manager

Watchlist

Price: 0.99 SEK -5.71% Market Closed

Market Cap: kr23.5m

	ExpreS2ion Biotech Holding AB STO:EXPRS2	SE
	Propanc Biopharma Inc NASDAQ:PPCB	AU

Profitability Summary

ExpreS2ion Biotech Holding AB's profitability score is 18/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

86%

Negative 3Y Average Gross Margin

-30%

Gross Margin is Increasing

-142% > 86%

Negative Operating Margin

-181%

Negative 3Y Average Operating Margin

-680%

Operating Margin is Increasing

-1 745% > -181%

Negative Net Margin

-148%

Negative 3Y Average Net Margin

-479%

Net Margin is Increasing

-1 603% > -148%

Negative Free Cash Flow Margin

-198%

Negative 3Y Average Free Cash Flow Margin

-595%

Free Cash Flow Margin is Increasing

-2 115% > -198%

Negative ROE

-85%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-268%

ROIC is Increasing

-645% > -163%

View All

Hide

Collapse

18 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.